Photo: law. asia

Medical device provider Mindray has settled with its rival Biolight, ending all their ongoing patent litigation, according to an announcement from Biolight last Thursday.

The announcement revealed that Biolight and Mindray had signed a settlement agreement, and Biolight had received the civil mediation documents for the relevant cases, allowing Mindray to withdraw the lawsuits.

Further details about whether the settlement involves a license fee or an exclusive patent right to remove the infringing product from the market were not disclosed.

The settlement follows months of legal battles over multiple patents. Since August 2023, Mindray had filed six separate lawsuits for patent infringement in the Fuzhou Intermediate People's Court, targeting Biolight's "monitoring" products, specifically models P1 and P18, which are key products in Biolight's high-end intelligent monitoring line.

In 2023, Biolight's monitoring products generated approximately 381 million RMB in revenue, accounting for 31.89% of its total revenue.

The disputes involved three invention patents (ZL201780051006.3, ZL201810904411.1, and ZL200610157495.4) and one utility model patent (ZL201821286746.3), with each claim amounting to 10 million RMB, as well as two design patents (ZL201630419447.2 and ZL201630126309.5), with each claim amounting to 5 million RMB. Mindray's total claim was 50 million RMB.

The Fuzhou Intermediate People's Court awarded Mindray 986,300 RMB and 826,800 RMB respectively in the two design patent cases and 2,005,800 RMB in one of the invention patent cases. The other cases ended with Mindray withdrawing the lawsuits.